IRCT20150808023559N20
Recruiting
Phase 1
Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- COVID-19.
- Sponsor
- Ardabil University of Medical Sciences
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of COVID\-19 based on either ground glass appearance in chest CT scan or positive RT\-PCR test for COVID\-19
- •Requiring hospitalization
- •Patient's age between 16 and 100 years
- •Signed informed consent form
Exclusion Criteria
- •Receiving other antiviral medications
- •renal failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19IRCT20200318046812N1Iran University of Medical Sciences324
Recruiting
Phase 4
A Clinical Trial to Study the Safety and Efficacy of Hydroxychloroquine in Patients with Type-2 DaibetesHealth Condition 1: E118- Type 2 diabetes mellitus with unspecified complicationsCTRI/2016/02/006599Ipca Laboratories Ltd600
Recruiting
Phase 3
Treatment of Hydroxychloroquine in Type 2 Diabetes Patients Uncontrolled on Metformin MonotherapyHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2021/11/037750Ipca Laboratories Ltd
Recruiting
Phase 3
Evaluation the effects of Hydroxychloroquine administration for COVID-19 prophylaxisCOVID-19 pneumonia.COVID-19, virus not identifiedU07.2IRCT20130917014693N10Shahid Beheshti University of Medical Sciences100
Recruiting
Phase 2
Combination therapy in COVID 19COVID-19 pneumonia.IRCT20100228003449N30Tehran University of Medical Sciences50